Effects of glucagon on postprandial carbohydrate metabolism in nondiabetic humans. 1998

J W Frank, and M Camilleri, and G M Thomforde, and S F Dinneen, and R A Rizza
Gastroenterology Unit, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.

The present experiments sought to determine whether glucagon concentrations mimicking those observed in people with diabetes mellitus alter postprandial carbohydrate metabolism in nondiabetic humans. We measured the gastric emptying of solids and liquids, the systemic rate of appearance of ingested glucose, and endogenous glucose production either when postprandial suppression of glucagon was prevented by infusing glucagon at a rate of 0.65 ng/kg/min, when postprandial glucagon concentrations were elevated by infusing glucagon at a rate of 3.0 ng/kg/min, or when postprandial suppression of glucagon was permitted by infusion of saline. Despite marked differences in glucagon concentrations, postprandial glucose and insulin concentrations did not differ on any occasion. Although gastric emptying of liquids and solids was comparable on all three occasions, the high-dose, but not the low-dose, glucagon infusion caused a slight delay in the systemic appearance of ingested glucose and a significant decrease (P < .01) in postprandial D-xylose concentrations, suggesting a delay in carbohydrate absorption. However, this was offset by an increase (P < .05) in endogenous glucose production, resulting in no difference in postprandial glucose appearance. We conclude that in the absence of insulin deficiency, neither a lack of suppression of glucagon nor an elevation of glucagon to levels encountered in uncontrolled diabetes mellitus cause postprandial hyperglycemia in nondiabetic humans.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D005260 Female Females
D005502 Food Substances taken in by the body to provide nourishment. Foods
D005746 Gastric Emptying The evacuation of food from the stomach into the duodenum. Emptying, Gastric,Emptyings, Gastric,Gastric Emptyings
D005768 Gastrointestinal Hormones HORMONES secreted by the gastrointestinal mucosa that affect the timing or the quality of secretion of digestive enzymes, and regulate the motor activity of the digestive system organs. Enteric Hormone,Enteric Hormones,Gastrointestinal Hormone,Intestinal Hormone,Intestinal Hormones,Hormone, Enteric,Hormone, Gastrointestinal,Hormone, Intestinal,Hormones, Enteric,Hormones, Gastrointestinal,Hormones, Intestinal
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor

Related Publications

J W Frank, and M Camilleri, and G M Thomforde, and S F Dinneen, and R A Rizza
June 1986, Prostaglandins,
J W Frank, and M Camilleri, and G M Thomforde, and S F Dinneen, and R A Rizza
February 1991, The Journal of clinical endocrinology and metabolism,
J W Frank, and M Camilleri, and G M Thomforde, and S F Dinneen, and R A Rizza
June 1956, Canadian Medical Association journal,
J W Frank, and M Camilleri, and G M Thomforde, and S F Dinneen, and R A Rizza
July 2021, Medicine and science in sports and exercise,
J W Frank, and M Camilleri, and G M Thomforde, and S F Dinneen, and R A Rizza
September 1962, Nihon Naibunpi Gakkai zasshi,
J W Frank, and M Camilleri, and G M Thomforde, and S F Dinneen, and R A Rizza
August 1956, Minerva pediatrica,
J W Frank, and M Camilleri, and G M Thomforde, and S F Dinneen, and R A Rizza
November 2001, The Journal of experimental zoology,
J W Frank, and M Camilleri, and G M Thomforde, and S F Dinneen, and R A Rizza
March 1970, The Journal of clinical endocrinology and metabolism,
J W Frank, and M Camilleri, and G M Thomforde, and S F Dinneen, and R A Rizza
August 1975, Metabolism: clinical and experimental,
J W Frank, and M Camilleri, and G M Thomforde, and S F Dinneen, and R A Rizza
October 2014, Arteriosclerosis, thrombosis, and vascular biology,
Copied contents to your clipboard!